A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

NCT05093322 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma
Osteosarcoma
Ewing Sarcoma
Rhabdomyosarcoma
Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Interventions

DRUG: Surufatinib in combination with Gemcitabine

Sponsor

Hutchmed